Viatris Inc. (VIA.F)

10,97 +0,22 (+2,00%) Börsenschluss: 04:01PM CEST

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800
https://www.viatris.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 38.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Scott Andrew Smith	CEO & Director	4,73M	N/A	1962
Mr. Andrew Enrietti	Chief People Officer	N/A	N/A	N/A
Mr. Menassie Taddese M.B.A.	President of Emerging Markets	N/A	N/A	1970
Mr. Derek Glover	Chief Quality Officer	N/A	N/A	N/A
Ms. Lara Ramsburg	Chief Corporate Affairs Officer	N/A	N/A	N/A
Dr. Jeffrey Nau MMS, Ph.D.	President of Viatris Eye Care Division	N/A	N/A	1976
Mr. Philippe Martin	Chief R&D Officer	N/A	N/A	1975
Dr. Corinne M. Le Goff M.B.A., Pharm.D.	Chief Commercial Officer	N/A	N/A	1965
Mr. Peter McCormick	Chief Supply Officer	N/A	N/A	N/A
Mr. Burt Park	Chief Governance Counsel & Corporate Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Corporate Governance

Viatris Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 2, Vorstand: 9, Shareholderrechte: 6, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.